SB-649915, a novel, potent 5-HT1A and 5-HT1B autoreceptor antagonist and 5-HT re-uptake inhibitor in native tissue.
暂无分享,去创建一个
Christopher J Langmead | Jeannette Watson | C. Langmead | J. Hagan | C. Scott | G. W. Price | S. Bromidge | Christopher N. Johnson | J. Watson | Gary W Price | Peter J Atkinson | P. Atkinson | Claire Scott | Ellen M Soffin | Matthew Hill | Paul B Wren | Stefania Faedo | Laurie J Gordon | Steve Bromidge | Christopher N Johnson | James J Hagan | P. Wren | E. Soffin | S. Faedo | Matthew J. Hill | Laurie J. Gordon
[1] E. Meller,et al. Repeated treatment with antidepressants differentially alters 5-HT1A agonist-stimulated [35S]GTPγS binding in rat brain regions , 2002, Neuropharmacology.
[2] G. W. Price,et al. Interaction of serotonin autoreceptor antagonists in the rat dorsal raphe nucleus: an in vitro fast cyclic voltammetry study , 2001, Neuroscience Letters.
[3] R. Pihl,et al. Tryptophan depletion causes a rapid lowering of mood in normal males , 2004, Psychopharmacology.
[4] D. Middlemiss,et al. Enhancement of 5-HT1B and 5-HT1D receptor antagonist effects on extracellular 5-HT levels in the guinea-pig brain following concurrent 5-HT1A or 5-HT re-uptake site blockade , 1999, Neuropharmacology.
[5] D. Middlemiss,et al. SB‐224289–a novel selective (human) 5‐HT1B receptor antagonist with negative intrinsic activity , 1998, British journal of pharmacology.
[6] I. Forbes,et al. In vitro and in vivo profile of SB 206553, a potent 5‐HT2C/5‐HT2B receptor antagonist with anxiolytic‐like properties , 1996, British Journal of Pharmacology.
[7] D. Middlemiss,et al. 3,4-Dihydro-2H-benzoxazinones are 5-HT(1A) receptor antagonists with potent 5-HT reuptake inhibitory activity. , 2005, Bioorganic & medicinal chemistry letters.
[8] L. Lanfumey,et al. Antagonist properties of (−)‐pindolol and WAY 100635 at somatodendritic and postsynaptic 5‐HT1A receptors in the rat brain , 1998, British journal of pharmacology.
[9] D. Middlemiss,et al. GR127935 acts as a partial agonist at recombinant human 5-HT1Dα and 5-HT1Dβ receptors , 1996 .
[10] S. Z. Langer,et al. Pharmacological characterization of the cloned human 5-hydroxytryptamine transporter. , 1996, Biochemical pharmacology.
[11] W. P. Bowen,et al. Nonlinear regression using spreadsheets. , 1995, Trends in pharmacological sciences.
[12] M. Raiteri,et al. Pharmacological diversity between native human 5‐HT1B and 5‐HT1D receptors sited on different neurons and involved in different functions , 1999, British journal of pharmacology.
[13] D. Middlemiss,et al. Effects of selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.
[14] J. Stamford,et al. Evidence that 5‐hydroxytryptamine release in rat dorsal raphé nucleus is controlled by 5‐HT1A, 5‐HT1B and 5‐HT1D autoreceptors , 1995, British journal of pharmacology.
[15] B. Shopsin. Enhancement of the antidepressant response to L-tryptophan by a liver pyrrolase inhibitor: a rational treatment approach. , 1978, Neuropsychobiology.
[16] P. Celada,et al. How does pindolol improve antidepressant action? , 2001, Trends in pharmacological sciences.
[17] L. D. van de Kar,et al. Chronic fluoxetine-induced desensitization of 5-HT1A and 5-HT1B autoreceptors: regional differences and effects of WAY-100635. , 2004, European journal of pharmacology.
[18] J. Hagan,et al. The effect of SB-236057-A, a selective 5-HT1B receptor inverse agonist, on in vivo extracellular 5-HT levels in the freely-moving guinea-pig , 2000, Naunyn-Schmiedeberg's Archives of Pharmacology.
[19] J. Hensler,et al. Differential Regulation of 5-HT1A Receptor-G Protein Interactions in Brain Following Chronic Antidepressant Administration , 2002, Neuropsychopharmacology.
[20] Y. Cheng,et al. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.
[21] S. Mitchell,et al. The role of the 5-HT1D receptor as a presynaptic autoreceptor in the guinea pig. , 2004, European journal of pharmacology.
[22] L. Dawson,et al. The role of 5-HT1A and 5-HT1B/1D receptors on the modulation of acute fluoxetine-induced changes in extracellular 5-HT: the mechanism of action of (±)pindolol , 2000, Neuropharmacology.
[23] T. Sharp,et al. Effect of a selective 5‐HT reuptake inhibitor in combination with 5‐HT1A and 5‐HT1B receptor antagonists on extracellular 5‐HT in rat frontal cortex in vivo , 1997, British journal of pharmacology.
[24] L. D. van de Kar,et al. Daily injections of fluoxetine induce dose-dependent desensitization of hypothalamic 5-HT1A receptors: reductions in neuroendocrine responses to 8-OH-DPAT and in levels of Gz and Gi proteins. , 1999, The Journal of pharmacology and experimental therapeutics.
[25] S. J. Starkey,et al. GR127935: a potent and selective 5-HT1D receptor antagonist , 1995, Behavioural Brain Research.
[26] I. Lucki,et al. Effects of acute and repeated administration of antidepressant drugs on extracellular levels of 5-hydroxytryptamine measured in vivo. , 1995, The Journal of pharmacology and experimental therapeutics.
[27] B. O'dowd,et al. A single amino-acid difference confers major pharmacological variation between human and rodent 5-HT1B receptors , 1992, Nature.
[28] S. Mir,et al. Pindolol augmentation of antidepressant therapy , 1998, British Journal of Psychiatry.
[29] T. Branchek,et al. The rat 5-hydroxytryptamine1B receptor is the species homologue of the human 5-hydroxytryptamine1D beta receptor. , 1992, Molecular pharmacology.
[30] C. Montigny,et al. Long-term 5-HT reuptake blockade, but not monoamine oxidase inhibition, decreases the function of terminal 5-HT autoreceptors: an electrophysiological study in the rat brain , 1988, Naunyn-Schmiedeberg's Archives of Pharmacology.
[31] D. Middlemiss,et al. SB-236057, a selective 5-HT1B receptor inverse agonist, blocks the 5-HT human terminal autoreceptor. , 1999, European journal of pharmacology.
[32] P. Blier,et al. Modulation of 5‐HT release in the guinea‐pig brain following long‐term administration of antidepressant drugs , 1994, British journal of pharmacology.
[33] C. Montigny,et al. Electrophysiological investigations on the effect of repeated zimelidine administration on serotonergic neurotransmission in the rat , 1983, The Journal of neuroscience : the official journal of the Society for Neuroscience.
[34] N. A. Manuel,et al. Ketanserin‐sensitive depressant actions of 5‐HT receptor agonists in the neonatal rat spinal cord , 1995, British journal of pharmacology.
[35] P. Cowen,et al. Pindolol augmentation of selective serotonin reuptake inhibitors: PET evidence that the dose used in clinical trials is too low. , 2001, The American journal of psychiatry.
[36] P. Nathan,et al. Pindolol augmentation of selective serotonin reuptake inhibitors: Accounting for the variability of results of placebo‐controlled double‐blind studies in patients with major depression , 2005, Human psychopharmacology.
[37] Repeated administration of the 5-HT1B receptor antagonist SB-224289 blocks the desensitisation of 5-HT1B autoreceptors induced by fluoxetine in rat frontal cortex , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[38] C. Scott,et al. 5‐HT1A receptor agonist‐antagonist binding affinity difference as a measure of intrinsic activity in recombinant and native tissue systems , 2000, British journal of pharmacology.
[39] D. Thomas,et al. Biochemical effects of the antidepressant paroxetine, a specific 5-hydroxytryptamine uptake inhibitor , 2004, Psychopharmacology.
[40] M. Hamon,et al. Autoradiographic evidence for the heterogeneity of 5-HT1 sites in the rat brain , 1984, Brain Research.
[41] G. W. Price,et al. Functional characterization of the 5‐HT terminal autoreceptor in the guinea‐pig brain cortex , 1996, British journal of pharmacology.